An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria
| Autor: | Darrell E. Singer, Terfa Kene, Jennifer A. Malia, Ogbonnaya S. Njoku, Sheila A. Peel, Abraham S. Alabi, Mark M. Manak, Aminu Suleiman, Robbie Nelson, Gideon Akindiran Akintunde, Merlin L. Robb, Nelson L. Michael, Richard A. Heipertz, Robert J. O'Connell, Amos A. Ogundeji, Mark Milazzo, Sodsai Tovanabutra, Ashley Shutt, Ojor Ayemoba |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
RNA viruses
Male 0301 basic medicine Epidemiology Cross-sectional study lcsh:Medicine HIV Infections Pathology and Laboratory Medicine Geographical Locations 0302 clinical medicine Immunodeficiency Viruses Risk Factors Surveys and Questionnaires Medicine and Health Sciences Prevalence Medicine 030212 general & internal medicine Young adult lcsh:Science AIDS Vaccines Vaccines Univariate analysis Multidisciplinary virus diseases Middle Aged Hepatitis B Institutional review board Hepatitis C Medical Microbiology HIV epidemiology Viral Pathogens Viruses Host-Pathogen Interactions Cohort Infectious diseases Vaccination and immunization Marital status Female Pathogens Research Article Adult Adolescent Immunology Nigeria Viral diseases Microbiology Young Adult 03 medical and health sciences Virology Environmental health Retroviruses Vaccine Development Humans Microbial Pathogens Preventive medicine Acquired Immunodeficiency Syndrome Viral vaccines business.industry Hiv 1 vaccine Lentivirus lcsh:R Organisms HIV vaccines Biology and Life Sciences HIV Patient Acceptance of Health Care Public and occupational health Cross-Sectional Studies 030104 developmental biology People and Places Africa HIV-2 HIV-1 Optometry lcsh:Q Observational study business |
| Zdroj: | PLoS ONE, Vol 11, Iss 12, p e0166711 (2016) PLoS ONE |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0166711 |
| Popis: | Development of a globally effective HIV-1 vaccine will need to encompass Nigeria, one of the hardest hit areas, with an estimated 3.2 million people living with HIV. This cross-sectional Institutional Review Board (IRB) approved study was conducted in 2009–12 at four market sites and two highway settlements sites in Nigeria to identify and characterize populations at high risk for HIV; engage support of local stakeholders; and assess the level of interest in future vaccine studies. Demographic, HIV risk data were collected by structured interviewer-administered questionnaires. Blood samples were tested on site by HIV rapid diagnostic tests, followed by rigorous confirmatory testing, subtype evaluation and testing for HBV and HCV markers in a clinical reference laboratory. Of 3229 study participants, 326 were HIV infected as confirmed by Western Blot or RNA, with a HIV prevalence of 15.4%-23.9% at highway settlements and 3.1%-9.1% at market sites. There was no observable correlation of prevalence of HIV-1 (10.1%) with HBV (10.9%) or HCV (2.9%). Major HIV-1 subtypes included CRF02_AG (37.5%); G (27.5%); G/CRF02_AG (25.9%); and non-typeable (8.9%), with 0.3% HIV-2. Univariate analysis found age, gender, marital status, level of education, and sex under substance influence as significant risk factors for HIV (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|